Cargando…
Efficacy of diet restriction with or without probiotic for treatment of patients with IBS‐D: Phase I−II clinical trial
BACKGROUND AND AIM: Diet is a major contributor to irritable bowel syndrome (IBS) and is also a powerful tool for treatment of IBS. This study compared two diets and explored the effectiveness of the diets when combined with a probiotic for treatment of IBS‐D patients. METHODS: Phase I, patients wer...
Autores principales: | Zhao, Xian‐Shu, Shi, Li‐Jun, Ning, Bao‐Li, Zhao, Zhi‐Ming, Li, Xiao‐Xue, Zhu, Meng‐Hua, Zhang, Ya‐Bing, Fu, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165954/ https://www.ncbi.nlm.nih.gov/pubmed/37249280 http://dx.doi.org/10.1002/iid3.857 |
Ejemplares similares
-
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
por: Ida, Hanae, et al.
Publicado: (2023) -
A phase Ib/II study of fruquintinib in combination with paclitaxel as the second‐line therapy for advanced gastric cancer
por: Zhang, Yang, et al.
Publicado: (2022) -
Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
por: Wang, Feng, et al.
Publicado: (2021) -
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
por: Wakelee, Heather A., et al.
Publicado: (2017) -
Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study
por: Liu, Chengxin, et al.
Publicado: (2023)